78 related articles for article (PubMed ID: 16426053)
1. A multivariate analysis of HIV-1 protease inhibitors and resistance induced by mutation.
Almerico AM; Tutone M; Lauria A; Diana P; Barraja P; Montalbano A; Cirrincione G; Dattolo G
J Chem Inf Model; 2006; 46(1):168-79. PubMed ID: 16426053
[TBL] [Abstract][Full Text] [Related]
2. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL
Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735
[TBL] [Abstract][Full Text] [Related]
3. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
Perryman AL; Lin JH; Andrew McCammon J
Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
[TBL] [Abstract][Full Text] [Related]
4. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
[TBL] [Abstract][Full Text] [Related]
5. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
[TBL] [Abstract][Full Text] [Related]
6. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
[TBL] [Abstract][Full Text] [Related]
7. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
[TBL] [Abstract][Full Text] [Related]
8. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
[TBL] [Abstract][Full Text] [Related]
9. Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Mo H; Parkin N; Stewart KD; Lu L; Dekhtyar T; Kempf DJ; Molla A
Antimicrob Agents Chemother; 2007 Feb; 51(2):732-5. PubMed ID: 17101675
[TBL] [Abstract][Full Text] [Related]
10. P1-substituted symmetry-based human immunodeficiency virus protease inhibitors with potent antiviral activity against drug-resistant viruses.
Degoey DA; Grampovnik DJ; Chen HJ; Flosi WJ; Klein LL; Dekhtyar T; Stoll V; Mamo M; Molla A; Kempf DJ
J Med Chem; 2011 Oct; 54(20):7094-104. PubMed ID: 21899332
[TBL] [Abstract][Full Text] [Related]
11. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
Hou T; Yu R
J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
[TBL] [Abstract][Full Text] [Related]
12. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives.
Martinez-Cajas JL; Wainberg MA
Antiviral Res; 2007 Dec; 76(3):203-21. PubMed ID: 17673305
[TBL] [Abstract][Full Text] [Related]
13. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J
J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839
[TBL] [Abstract][Full Text] [Related]
14. Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.
Flosi WJ; DeGoey DA; Grampovnik DJ; Chen HJ; Klein LL; Dekhtyar T; Masse S; Marsh KC; Mo HM; Kempf D
Bioorg Med Chem; 2006 Oct; 14(19):6695-712. PubMed ID: 16828558
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes.
Aruksakunwong O; Wolschann P; Hannongbua S; Sompornpisut P
J Chem Inf Model; 2006; 46(5):2085-92. PubMed ID: 16995739
[TBL] [Abstract][Full Text] [Related]
16. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
17. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
[TBL] [Abstract][Full Text] [Related]
18. The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts.
Sista P; Wasikowski B; Lecocq P; Pattery T; Bacheler L
J Clin Virol; 2008 Aug; 42(4):405-8. PubMed ID: 18472298
[TBL] [Abstract][Full Text] [Related]
19. Proteochemometric modeling of drug resistance over the mutational space for multiple HIV protease variants and multiple protease inhibitors.
Lapins M; Wikberg JE
J Chem Inf Model; 2009 May; 49(5):1202-10. PubMed ID: 19391634
[TBL] [Abstract][Full Text] [Related]
20. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
